Neuren is significant undervalued ..
Neuren Pharma ( NEU.AX)
Marketcap: only 48 million A$
Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG Phase 3 ongoing
NNZ-2566 Severe TBI (traumatic brain injury) Phase 2a (deal with US Army)
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Post-stroke-Apathy Phase 2b
Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva™ in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate® in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.
- Forums
- ASX - By Stock
- IMU
- cheapest biotech stock on the asx
cheapest biotech stock on the asx
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $394.1M |
Open | High | Low | Value | Volume |
5.4¢ | 5.5¢ | 5.3¢ | $817.0K | 15.17M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 4719788 | 5.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 453183 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 4719788 | 0.053 |
33 | 5699555 | 0.052 |
41 | 5272705 | 0.051 |
75 | 5782253 | 0.050 |
13 | 2760364 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 453183 | 5 |
0.055 | 2280320 | 12 |
0.056 | 1338592 | 11 |
0.057 | 1025942 | 7 |
0.058 | 797977 | 5 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |